Literature DB >> 9088799

Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms.

H J Möller1, H Müller.   

Abstract

The differentiation between primary and secondary negative symptoms in schizophrenia (Carpenter et al. 1985) is an important issue. Path analysis allows to estimate statistically whether, and in which degree, the effect of a neuroleptic on negative symptoms is mediated by effects on positive, extrapyramidal, and depressive symptoms (Möller et al. 1995). If certain causal relationships are theoretically assumed-as proposed by Carpenter et al. (1985)-then path analysis can be applied to estimate the quantitative degree of these relationships, although the causal directions cannot be inferred from path analysis itself. Especially it can be estimated whether there is sufficient evidence for a "direct effect" of neuroleptic treatment on (primary) negative symptoms, an effect which is not mediated by positive, extrapyramidal, and/or depressive symptoms. We show the correspondence between the applied path model and several simple regression equations which can be estimated with standard statistical software. Moreover, we report some Monte Carlo studies showing that the results reported by Möller et al. (1995)-a "direct effect" of risperidone (6 mg) on negative symptoms compared with haloperidol (20 mg)-cannot be explained by a path model in which, everything else being equal, positive symptoms depend on negative symptoms instead of the other way around.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088799     DOI: 10.1007/bf02916246

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  5 in total

1.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

2.  Treatment of negative symptoms.

Authors:  W T Carpenter; D W Heinrichs; L D Alphs
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

3.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 4.  Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.

Authors:  H J Möller
Journal:  Eur Neuropsychopharmacol       Date:  1993-03       Impact factor: 4.600

5.  Risperidone in the treatment of schizophrenia.

Authors:  S R Marder; R C Meibach
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.